Advertisement

Long-term clinical outcome after intramuscular transplantation of granulocyte colony stimulating factor-mobilized CD34 positive cells in patients with critical limb ischemia

      Abstract

      Background

      Our phase I/IIa clinical trial revealed that intramuscular transplantation of autologous, GCSF-mobilized CD34+ cells was safe, feasible and potentially effective at week 4 and 12 post cellular therapy in 17 patients with chronic critical limb ischemia (CLI) (5 patients with atherosclerotic peripheral arterial disease (PAD) and 12 with Buerger's disease). However, long-term outcome of the cell therapy has yet to be reported.

      Methods and results

      Incidence of major clinical events and physiological parameters of limb ischemia were evaluated at week 52, 104, 156 and 208 post CD34+ cell therapy. No patients died by week 104, whereas 3 patients with PAD died by week 156 and 1 patient with Buerger's disease died by week 208 due to cardiac complications. No patients underwent major amputation, whereas 1 patient with Buerger's disease underwent unplanned minor amputation by week 104. CLI-free ratio was 88.2% at week 52 and 104, 92.3% at week 156 and 84.6% at week 208 in all patients. Significant improvement of toe brachial pressure index versus baseline was sustained up to week 208 and that of transcutaneous partial oxygen pressure was kept up to week 156. The Wong-Baker FACES pain rating scale, ulcer size and exercise tolerance significantly improved at week 52, the final evaluation time point, compared with baseline. Subgroup analysis revealed the similar outcome in patients with Buerger's disease.

      Conclusions

      Favorable clinical outcomes as well as physiological evidences strongly indicate the long-term benefit of GCSF-mobilized CD34+ cell transplantation for retrieval from CLI, especially in patients with Buerger's disease.

      Highlights

      • The first clinical report of long-term outcome of CD34+ cell therapy in CLI.
      • High CLI-free ratio was sustained for 4 years post CD34+ cell therapy.
      • Significant improvement of TBPI and TcPO2 was sustained for 3–4 years.
      • Favorable outcomes indicate long-term benefit of the cell therapy for CLI patients.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hirsch A.T.
        • Haskal Z.J.
        • Hertzer N.R.
        • et al.
        ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American association for vascular surgery/society for vascular surgery, society for cardiovascular angiography and interventions, society for vascular medicine and biology, society of interventional radiology, and the ACC/AHA task force on practice guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease) endorsed by the American association of cardiovascular and pulmonary rehabilitation; national heart, lung, and blood institute; society for vascular nursing; transatlantic inter-society consensus; and vascular disease foundation.
        J Am Coll Cardiol. 2006; 47: 1239-1312
        • Norgren L.
        • Hiatt W.R.
        • Dormandy J.A.
        • Nehler M.R.
        • Harris K.A.
        • Fowkes F.G.
        Inter-society consensus for the management of peripheral arterial disease (TASC II).
        J Vasc Surg. 2007; 45: S5-67
        • Asahara T.
        • Murohara T.
        • Sullivan A.
        • et al.
        Isolation of putative progenitor endothelial cells for angiogenesis.
        Science. 1997; 275: 964-967
        • Kalka C.
        • Masuda H.
        • Takahashi T.
        • et al.
        Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization.
        Proc Natl Acad Sci U S A. 2000; 97: 3422-3427
        • Kawamoto A.
        • Gwon H.C.
        • Iwaguro H.
        • et al.
        Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia.
        Circulation. 2001; 103: 634-637
        • Taguchi A.
        • Soma T.
        • Tanaka H.
        • et al.
        Administration of CD34+ cells after stroke enhances neurogenesis via angiogenesis in a mouse model.
        J Clin Invest. 2004; 114: 330-338
        • Tateishi-Yuyama E.
        • Matsubara H.
        • Murohara T.
        • et al.
        Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial.
        Lancet. 2002; 360: 427-435
        • Tateno K.
        • Minamino T.
        • Toko H.
        • et al.
        Critical roles of muscle-secreted angiogenic factors in therapeutic neovascularization.
        Circ Res. 2006; 98: 1194-1202
        • Onodera R.
        • Teramukai S.
        • Tanaka S.
        • et al.
        Bone marrow mononuclear cells versus G-CSF-mobilized peripheral blood mononuclear cells for treatment of lower limb ASO: pooled analysis for long-term prognosis.
        Bone Marrow Transplant. 2011; 46: 278-284
        • Kawamoto A.
        • Katayama M.
        • Handa N.
        • et al.
        Intramuscular transplantation of G-CSF-mobilized CD34(+) cells in patients with critical limb ischemia: a phase I/IIa, multicenter, single-blinded, dose-escalation clinical trial.
        Stem Cells. 2009; 27: 2857-2864
        • Burt R.K.
        • Testori A.
        • Oyama Y.
        • et al.
        Autologous peripheral blood CD133+ cell implantation for limb salvage in patients with critical limb ischemia.
        Bone Marrow Transplant. 2010; 45: 111-116
        • Matoba S.
        • Tatsumi T.
        • Murohara T.
        • et al.
        Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (therapeutic angiogenesis by cell transplantation [TACT] trial) in patients with chronic limb ischemia.
        Am Heart J. 2008; 156: 1010-1018
        • Moriya J.
        • Minamino T.
        • Tateno K.
        • et al.
        Long-term outcome of therapeutic neovascularization using peripheral blood mononuclear cells for limb ischemia.
        Circ Cardiovasc Interv. 2009; 2: 245-254
        • Horie T.
        • Onodera R.
        • Akamastu M.
        • et al.
        Long-term clinical outcomes for patients with lower limb ischemia implanted with G-CSF-mobilized autologous peripheral blood mononuclear cells.
        Atherosclerosis. 2010; 208: 461-466
        • Idei N.
        • Soga J.
        • Hata T.
        • et al.
        Autologous bone-marrow mononuclear cell implantation reduces long-term major amputation risk in patients with critical limb ischemia: a comparison of atherosclerotic peripheral arterial disease and Buerger disease.
        Circ Cardiovasc Interv. 2011; 4: 15-25
        • Miyamoto K.
        • Nishigami K.
        • Nagaya N.
        • et al.
        Unblinded pilot study of autologous transplantation of bone marrow mononuclear cells in patients with thromboangiitis obliterans.
        Circulation. 2006; 114: 2679-2684
        • Vasa M.
        • Fichtlscherer S.
        • Aicher A.
        • et al.
        Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease.
        Circ Res. 2001; 89: E1-E7
        • Tepper O.M.
        • Galiano R.D.
        • Capla J.M.
        • et al.
        Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures.
        Circulation. 2002; 106: 2781-2786
        • Yamamoto K.
        • Kondo T.
        • Suzuki S.
        • et al.
        Molecular evaluation of endothelial progenitor cells in patients with ischemic limbs: therapeutic effect by stem cell transplantation.
        Arterioscler Thromb Vasc Biol. 2004; 24: e192-e196
        • Losordo D.W.
        • Henry T.D.
        • Davidson C.
        • et al.
        Intramyocardial, autologous CD34+ cell therapy for refractory angina.
        Circ Res. 2011; 109: 428-436
        • Mifune Y.
        • Matsumoto T.
        • Kawamoto A.
        • et al.
        Local delivery of granulocyte colony stimulating factor-mobilized CD34-positive progenitor cells using bioscaffold for modality of unhealing bone fracture.
        Stem Cells. 2008; 26: 1395-1405
        • Nakamura T.
        • Tsutsumi V.
        • Torimura T.
        • et al.
        Human peripheral blood CD34-positive cells enhance therapeutic regeneration of chronically injured liver in nude rats.
        J Cell Physiol. 2012; 227: 1538-1552
        • Huang P.
        • Li S.
        • Han M.
        • Xiao Z.
        • Yang R.
        • Han Z.C.
        Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes.
        Diabetes Care. 2005; 28: 2155-2160
        • Prochazka V.
        • Gumulec J.
        • Jaluvka F.
        • et al.
        Cell therapy, a new standard in management of chronic critical limb ischemia and foot ulcer.
        Cell Transplant. 2010; 19: 1413-1424
        • Walter D.H.
        • Krankenberg H.
        • Balzer J.O.
        • et al.
        Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia: a randomized-start, placebo-controlled pilot trial (PROVASA).
        Circ Cardiovasc Interv. 2011; 4: 26-37
        • Benoit E.
        • O'Donnell Jr., T.F.
        • Iafrati M.D.
        • et al.
        The role of amputation as an outcome measure in cellular therapy for critical limb ischemia: implications for clinical trial design.
        J Transl Med. 2011; 9: 165
        • Iafrati M.D.
        • Hallett J.W.
        • Geils G.
        • et al.
        Early results and lessons learned from a multicenter, randomized, double-blind trial of bone marrow aspirate concentrate in critical limb ischemia.
        J Vasc Surg. 2011; 54: 1650-1658